These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18619447)

  • 1. Biomarkers and photodynamic therapy for Barrett's esophagus: time to FISH or cut bait?
    Spechler SJ; Souza RF
    Gastroenterology; 2008 Aug; 135(2):354-7. PubMed ID: 18619447
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.
    Prasad GA; Wang KK; Halling KC; Buttar NS; Wongkeesong LM; Zinsmeister AR; Brankley SM; Fritcher EG; Westra WM; Krishnadath KK; Lutzke LS; Borkenhagen LS
    Gastroenterology; 2008 Aug; 135(2):370-9. PubMed ID: 18538141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy for the treatment of patients with Barrett's high-grade dysplasia and mucosal adenocarcinoma.
    Triadafilopoulos G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):136-7. PubMed ID: 16265153
    [No Abstract]   [Full Text] [Related]  

  • 4. [Photodynamic therapy of dysplasia and early cancer of the esophagus].
    Gossner L; Ell C
    Leber Magen Darm; 1996 May; 26(3):132, 135-7. PubMed ID: 8709826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia.
    Gill KR; Wolfsen HC; Preyer NW; Scott MV; Gross SA; Wallace MB; Jones LR
    Clin Cancer Res; 2009 Mar; 15(5):1830-6. PubMed ID: 19240171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modern aspects of photodynamic therapy of esophageal].
    Duvanskiĭ VA; Kniazev MV; Pravednikov PV
    Eksp Klin Gastroenterol; 2011; (10):111-6. PubMed ID: 22629709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus.
    Doak SH; Saidely D; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Exp Mol Pathol; 2004 Aug; 77(1):26-33. PubMed ID: 15215047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
    Wang XW; Gao HJ; Fang DC
    J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers and genetics in cancer development.
    Hormi-Carver K; Souza RF
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
    Rauser S; Weis R; Braselmann H; Feith M; Stein HJ; Langer R; Hutzler P; Hausmann M; Lassmann S; Siewert JR; Höfler H; Werner M; Walch A
    Clin Cancer Res; 2007 Sep; 13(17):5115-23. PubMed ID: 17785566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of in situ dosimetry during photodynamic therapy of Barrett's esophagus.
    van Veen RL; Robinson DJ; Siersema PD; Sterenborg HJ
    Gastrointest Endosc; 2006 Nov; 64(5):786-8. PubMed ID: 17055875
    [No Abstract]   [Full Text] [Related]  

  • 15. Photofrin to treat precancerous lesions in Barrett's esophagus.
    FDA Consum; 2003; 37(6):4. PubMed ID: 14983805
    [No Abstract]   [Full Text] [Related]  

  • 16. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus.
    Prasad GA; Wang KK; Halling KC; Buttar NS; Wongkeesong LM; Zinsmeister AR; Brankley SM; Westra WM; Lutzke LS; Borkenhagen LS; Dunagan K
    Cancer; 2008 Aug; 113(3):470-6. PubMed ID: 18553366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment.
    Panjehpour M; Coppola D; Overholt BF; Vo-Dinh T; Overholt S
    Anticancer Res; 2008; 28(1B):485-9. PubMed ID: 18383889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomere shortening in Barrett's mucosa and esophageal adenocarcinoma and its association with loss of heterozygosity.
    Shiraishi H; Mikami T; Aida J; Nakamura K; Izumiyama-Shimomura N; Arai T; Watanabe M; Okayasu I; Takubo K
    Scand J Gastroenterol; 2009; 44(5):538-44. PubMed ID: 19221928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.